Viemed Healthcare Inc (VMD)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $347.48M
Last updated: Nov 17, 2026 at 11:04 AM ET
Viemed Healthcare Inc (VMD) Financials: Revenue, Profit and Cash Flow
Viemed Healthcare reported revenue of $270.28M for the fiscal year ended Dec 31, 2025, up 20.5% from the year before. That year, net income was $15.38M with a net margin of 5.7%, operating cash flow was $51.92M and free cash flow was $11.93M. The quarter ended Sep 30, 2026 had revenue of $80.67M and net income of $4.74M.
Revenue and Margins
The operating margin was 8.5% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $31.36M, a compound annual rate of 27.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $270.28M | +20.5% | 57.5% | 8.5% | 5.7% |
| Dec 2024 | $224.26M | +22.5% | 59.4% | 8.0% | 5.1% |
| Dec 2023 | $183.01M | +31.8% | 61.6% | 7.8% | 5.6% |
| Dec 2022 | $138.83M | +18.6% | 61.0% | 5.9% | 4.5% |
| Dec 2021 | $117.06M | -10.8% | 62.7% | 9.9% | 7.8% |
| Dec 2020 | $131.31M | +63.6% | 61.0% | 20.4% | 24.0% |
| Dec 2019 | $80.26M | +24.5% | 69.8% | 11.0% | 10.6% |
| Dec 2018 | $64.46M | +37.4% | 74.1% | 15.6% | 14.7% |
| Dec 2017 | $46.93M | +49.7% | 73.8% | 18.8% | 17.4% |
| Dec 2016 | $31.36M | N/A | 60.1% | 1.2% | 3.9% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 34.8% from the year before. In the quarter ended Sep 2026, net income rose 31.7% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $270.28M | $224.26M | $183.01M | $138.83M | $117.06M | $131.31M | $80.26M | $64.46M | $46.93M | $31.36M |
| Cost of revenue | $114.82M | $91.05M | $70.22M | $54.15M | $43.65M | $51.20M | $24.25M | $16.69M | $12.31M | $12.50M |
| Gross profit | $155.46M | $133.20M | $112.78M | $84.68M | $73.41M | $80.11M | $56.01M | $47.77M | $34.62M | $18.86M |
| Research and development | $3.02M | $3.07M | $2.78M | $2.70M | $2.11M | $1.08M | $848.00K | $0 | $848.00K | $848.00K |
| Operating income | $22.95M | $17.90M | $14.33M | $8.25M | $11.58M | $26.78M | $8.86M | $10.06M | $8.82M | $383.00K |
| Net income | $15.38M | $11.41M | $10.24M | $6.22M | $9.13M | $31.53M | $8.53M | $9.51M | $8.18M | $1.23M |
| EBITDA | $52.04M | $43.28M | $36.29M | $24.87M | $22.89M | $36.36M | $15.62M | $13.63M | $11.37M | $1.81M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $80.67M | $78.10M | $75.41M | $76.18M | $71.91M | $63.06M | $59.13M | $60.70M | $58.00M | $54.97M | $50.59M | $50.74M |
| Gross profit | $46.19M | $45.05M | $42.83M | $44.10M | $41.34M | $36.73M | $33.28M | $36.14M | $34.37M | $32.89M | $29.80M | $32.11M |
| Operating income | $6.96M | $4.46M | $4.30M | $8.37M | $5.64M | $5.09M | $3.84M | $6.45M | $5.63M | $3.62M | $2.20M | $5.29M |
| Net income | $4.74M | $2.90M | $2.71M | $5.82M | $3.60M | $3.25M | $2.71M | $4.42M | $3.90M | $1.48M | $1.60M | $3.48M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $12.38M by $1.12M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $199.15M | $177.07M | $154.90M | $117.04M | $117.96M | $112.56M | $82.60M | $53.65M | $37.69M | $24.68M |
| Current assets | $48.49M | $52.88M | $38.37M | $39.74M | $47.31M | $47.17M | $27.81M | $23.09M | $17.00M | $11.20M |
| Cash and equivalents | $13.50M | $17.54M | $12.84M | $16.91M | $28.41M | $30.98M | $13.36M | $10.41M | $5.10M | $4.34M |
| Total liabilities | $55.63M | $43.77M | $41.00M | $19.95M | $23.14M | $30.87M | $38.90M | $21.08M | $13.95M | $11.80M |
| Short-term debt | $1.09M | $409.00K | $1.07M | $0 | $1.48M | $1.84M | $1.75M | $0 | $4.38M | $3.86M |
| Long-term debt | $11.29M | $3.59M | $6.00M | $0 | $4.31M | $5.80M | $7.63M | $0 | $0 | $0 |
| Shareholder equity | $141.54M | $131.39M | $113.89M | $97.09M | $94.82M | $81.69M | $43.70M | $32.57M | $23.74M | $12.88M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $207.63M | $204.22M | $197.36M | $214.94M | $202.36M | $184.60M | $178.08M | $177.07M | $169.53M | $163.95M | $154.88M | $154.90M |
| Total liabilities | $55.65M | $58.26M | $51.56M | $71.42M | $66.86M | $42.98M | $41.33M | $43.77M | $42.73M | $42.77M | $38.60M | $41.00M |
| Cash and equivalents | $9.68M | $10.68M | $9.76M | $13.50M | $11.12M | $20.02M | $10.16M | $17.54M | $11.35M | $8.81M | $7.31M | $12.84M |
| Shareholder equity | $150.09M | $144.03M | $143.86M | $141.54M | $133.61M | $139.73M | $134.76M | $131.39M | $124.96M | $119.37M | $116.27M | $113.89M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 23.0% of operating cash flow. Dividends and share repurchases together came to 114.0% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $51.92M | $39.09M | $45.21M | $27.75M | $22.49M | $35.11M | $19.09M | $22.37M | $12.02M | $6.41M |
| Capital expenditures | $39.98M | $38.77M | $26.11M | $23.04M | $20.34M | $13.04M | $13.38M | $6.11M | $4.00M | $1.67M |
| Free cash flow | $11.93M | $318.00K | $19.10M | $4.71M | $2.15M | $22.07M | $5.70M | $16.25M | $8.02M | $4.74M |
| Dividends paid | $374.00K | $36.00K | $0 | $0 | $111.01K | N/A | $405.21K | $0 | $0 | $0 |
| Share repurchases | $13.22M | $0 | $0 | $9.57M | $0 | $0 | $1.52M | $1.59M | N/A | N/A |
| Investing cash flow | -$50.17M | -$30.70M | -$52.11M | -$23.98M | -$19.75M | -$8.41M | -$12.81M | -$5.30M | -$3.57M | -$936.00K |
| Financing cash flow | -$5.79M | -$3.69M | $2.83M | -$15.27M | -$5.32M | -$9.07M | -$3.33M | -$11.75M | -$7.69M | -$4.29M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $11.49M | $15.90M | $8.07M | $18.44M | $18.37M | $12.25M | $2.85M | $14.99M | $12.74M | $10.18M | $1.18M | $13.28M |
| Capital expenditures | $8.62M | $8.46M | $6.71M | $8.74M | $7.64M | $8.13M | $15.48M | $12.83M | $11.00M | $8.93M | $6.01M | $7.95M |
| Free cash flow | $2.87M | $7.44M | $1.36M | $9.70M | $10.73M | $4.13M | -$12.63M | $2.16M | $1.74M | $1.25M | -$4.83M | $5.34M |
Frequently Asked Questions About VMD
What is Viemed Healthcare's annual revenue?
Viemed Healthcare reported revenue of $270.28M for the fiscal year ended Dec 31, 2025.
How fast is Viemed Healthcare's revenue growing?
Revenue was up 20.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 24.9%.
Is Viemed Healthcare profitable?
Yes. Viemed Healthcare reported net income of $15.38M for the fiscal year ended Dec 31, 2025, with a net margin of 5.7%.
How much free cash flow does VMD generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $51.92M minus capital expenditures of $39.98M produced free cash flow of $11.93M.
How much debt does Viemed Healthcare have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $11.29M, short-term debt of $1.09M and cash and equivalents of $13.50M.
VMD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors